Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
GENOSS Coronary Stent Clinical Trial

This study aims to evaluate the efficacy and safety of abluminal biodegradable polymer ultrathin sirolimus-eluting stent (Genoss stent) as compared with a durable-polymer everolimus-eluting

everolimus
acute coronary syndrome
coronary artery disease
stenosis
sirolimus
  • 0 views
  • 28 Jul, 2022
  • 1 location
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

sirolimus -eluting stent with abluminal grooves containing a biodegradable polymer in High Bleeding Risk patients with coronary artery disease.

clopidogrel
antiplatelet therapy
sirolimus
ischemia
bypass graft
  • 7 views
  • 01 Mar, 2022
  • 1 location
HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population

The study aims to evaluate the safety and efficacy of biodegradable polymer sirolimus-eluting coronary stent system (HELIOS) in patients with coronary artery disease . The primary endpoint is

arterial disease
revascularisation
infarct
sirolimus
myocardial infarction
  • 11 views
  • 03 Feb, 2022
  • 1 location
CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4 (SMART-CHOICE4)

(BioFreedom Ultra) with biodegradable polymer ultrathin sirolimus-eluting stents (Orsiro Mission) and prasugrel monotherapy after 1-month dual antiplatelet therapy (DAPT) of aspirin plus prasugrel with 12

prasugrel
unstable angina
antiplatelet therapy
stenosis
sirolimus
  • 0 views
  • 25 May, 2022
  • 1 location
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk

dapt
ejection fraction
aspirin
biodegradable polymer
sirolimus
  • 25 views
  • 01 Mar, 2022
  • 1 location
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial (HOST-IDEA)

comparison between sirolimus-eluting Orsiro stent with biodegradable polymer and polymer-free stent platform with the same antiproliferative agent, Coroflex ISAR stent system. At the same time, clopidogrel

cardiac death
coronary artery stenosis
clopidogrel
antiplatelet therapy
angina pectoris
  • 0 views
  • 26 Jan, 2022
  • 4 locations
Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes Mellitus (INC-DM)

Randomized, controlled, blind, single-center and non-inferiority clinical trial to compare the target lesion failure (TLF) at 12 months in patients with diabetes mellitus who underwent percutaneous coronary intervention with an Orsiro stent vs. Abluminus stent.

fasting
angiography
stenosis
sirolimus
ischemia
  • 0 views
  • 19 Jun, 2022
  • 1 location
Dose Escalation Study of Immunomodulatory Nanoparticles (PRECIOUS-01)

PRECIOUS-01 is an immunomodulating agent composed of the invariant natural killer T cell (iNKT) activator threitolceramide-6 (ThrCer6, IMM60) and the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) cancer-testis antigen peptides encapsulated in a poly(lactic-co-glycolic acid) (PLGA) nanoparticle. PRECIOUS-01 is being developed for the treatment of patients with NY-ESO-1-positive cancers.

  • 0 views
  • 25 Mar, 2022
  • 1 location
Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems

The TRANSLUMINA GmbH YuChooSeR Observatory is a prospective, multicentric post-marketing observatory designed to evaluate large scale safety and reliability of the Yukon Choice PC and the Yukon Chrome PC stents systems use in routine, clinical practice. This based observatory will enroll 2000 patients from 14 to 30 sites in France.

  • 0 views
  • 26 Jan, 2021
  • 7 locations
S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System

The primary objective of this registry is to evaluate the safety and efficacy of the Supraflex Family sirolimus-eluting coronary stent system in a 'real-world' patient population requiring stent implantation.

sirolimus
  • 17 views
  • 26 Feb, 2022
  • 4 locations